Insulin Glulisine
- Generic Name
- Insulin Glulisine
- Brand Names
- Apidra
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 207748-29-6
- Unique Ingredient Identifier
- 7XIY785AZD
- Background
Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insul...
- Indication
用于治疗成人糖尿病。
- Associated Conditions
- Diabetes Mellitus, Type 1 Diabetes Mellitus, Hyperglycemia during critical illness
- Associated Therapies
- -
Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting
- Conditions
- Interventions
- First Posted Date
- 2010-03-03
- Last Posted Date
- 2013-05-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 52
- Registration Number
- NCT01079364
- Locations
- 🇳🇱
Sanofi-Aventis Administrative Office, Gouda, Netherlands
A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone
- Conditions
- Interventions
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 14
- Registration Number
- NCT00979875
- Locations
- 🇺🇸
Profil Institute for Clinical Research, Inc., Chula Vista, California, United States
Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients
- Conditions
- Interventions
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2013-01-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 463
- Registration Number
- NCT00965549
- Locations
- 🇬🇧
Investigational Site Number 826-130, Bristol, United Kingdom
🇬🇧Investigational Site Number 826-149, Barnsley, United Kingdom
🇬🇧Investigational Site Number 826-136, Bradford, United Kingdom
Insulin Exposure and Glucose Response to Meals in Type 1 Diabetic Subjects Administered Two Different Insulin Regimens Compared to the Endogenous Insulin Exposure and Glucose Response to Meals In Healthy Adult Controls
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2014-12-11
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 24
- Registration Number
- NCT00927524
The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children
- Conditions
- Interventions
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Spectrum Health Hospitals
- Target Recruit Count
- 16
- Registration Number
- NCT00913497
- Locations
- 🇺🇸
Helen DeVos Childrens Hospital, Grand Rapids, Michigan, United States
Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes
- Conditions
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT00824668
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2008-02-05
- Last Posted Date
- 2010-08-31
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 289
- Registration Number
- NCT00607087
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery
- Conditions
- Interventions
- First Posted Date
- 2008-01-17
- Last Posted Date
- 2014-03-12
- Lead Sponsor
- Emory University
- Target Recruit Count
- 234
- Registration Number
- NCT00596687
- Locations
- 🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
Effect of Insulin Glulisine vs Regular Human Insulin on Postprandial Endothelial Function in Type 2 Diabetes
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2007-11-21
- Target Recruit Count
- 15
- Registration Number
- NCT00562133
- Locations
- 🇩🇪
Ikfe, Mainz, Rhineland-Palatinate, Germany
Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study
- Conditions
- Interventions
- First Posted Date
- 2007-10-04
- Last Posted Date
- 2009-09-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 98
- Registration Number
- NCT00539448
- Locations
- 🇦🇪
Sanofi-aventis administrative office, Dubai, United Arab Emirates
🇶🇦Sanofi-Aventis Administrative Office, Doha, Qatar
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.